Ximelagatran - Recent comparisons with warfarin

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 11, 2005, Pages 1943-1946

  Doggrell, Sheila A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Alanine aminotransferase; Atrial fibrillation; Clinical trial; Venous thromboembolism; Warfarin; Ximelagratan

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; RECURRENT DISEASE; STROKE; VENOUS THROMBOEMBOLISM;

EID: 25444465962     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.11.1943     Document Type: Article

References (10)

1. KEREIAKES DJ: Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition. Rev. Cardiovasc. Med. (2004) 5(Suppl. 5):S4-S11.
2. KATIRA R, CHAUHAN A, MORE RS: Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgrad. Med. J. (2005) 81:370-375.
3. KYRLE PA, EICHINGER S: Deep vein thrombosis. Lancet (2005) 365:1163-1174.
4. SCHULMAN S, WAHLANDER K, LUNDSTRÖM T et al.: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. (2003) 349:1713-1721.
5. EXECUTIVE STEERING COMMITTEE ON BEHALF OF THE SPORTIF III INVESTIGATORS: Stroke prevention with the oral direct thrombin inhibitor ximelagratan compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 362:1691-1698.
6. EXECUTIVE STEERING COMMITTEE ON BEHALF OF THE SPORTIF V INVESTIGATORS: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation - a randomized trial. JAMA (2005) 293:690-698.
7. ERIKSSON H, WAHLANDER K, GUSTAFSSON D et al.: A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. (2003) 1:41-47.
8. FIESSINGER J-N, HUISMAN MV, DAVIDSON BL et al.: Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - a randomized trial. JAMA (2005) 293:681-689.
9. LEE WM, LARREY D, OLSSON R et al.: Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. (2005) 28:351-379.
10. O'BRIEN CL, GAGE BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA (2005) 293:699-706.